2. Signaling Pathways
  3. Membrane Transporter/Ion Channel
  4. CFTR
  5. CFTR Agonist

CFTR Agonist

CFTR Agonists (6):

Cat. No. Product Name Effect Purity
  • HY-13017
    Ivacaftor
    		Agonist 99.90%
    Ivacaftor (VX-770) is a potent and orally bioavailable CFTR potentiator, targeting G551D-CFTR and F508del-CFTR with EC50s of 100 nM and 25 nM, respectively.
  • HY-111099
    GLPG1837
    		Agonist 99.86%
    GLPG1837 is a potent and reversible CFTR potentiator, with EC50s of 3 nM and 339 nM for F508del and G551D CFTR, respectively.
  • HY-158991
    I1421
    		Agonist
    I1421 is an activator of the cystic fibrosis transmembrane conductance regulator (CFTR) with an EC50 of 64 nM for WT CFTR currents. I1421 also allosterically activates multiple mutants causing cystic fibrosis (CF) with good in vivo potency, with an oral bioavailability of 60% in mice corresponding to a half-life of 75 min. I1421 synergizes with Elexacaftor (HY-111772) to enhance CFTR currents.
  • HY-13017A
    Ivacaftor benzenesulfonate
    		Agonist
    Ivacaftor benzenesulfonate is an orally bioavailable CFTR potentiator, used for cystic fibrosis treatment.
  • HY-13017B
    Ivacaftor hydrate
    		Agonist
    Ivacaftor hydrate (VX-770 hydrate) is an orally bioavailable CFTR potentiator, used for cystic fibrosis treatment.
  • HY-P3597
    Urocortin III (mouse) (free acid)
    		Agonist
    Urocortin III (mouse) (free acid) is a selective CRF2 receptor agonist (with high affinity for the CRF2 receptor). Urocortin III (mouse) (free acid) significantly inhibits gastric emptying without modifying colonic transit.